Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence (Q35057426)

6 August 2017

1 reference

title

Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence (English)

1 reference

6 August 2017

1 reference

1 reference

1 reference

Punam Mangtani

1 reference

6 August 2017

Felicity Cutts

series ordinal

1 reference

6 August 2017

Andrew J Hall

series ordinal

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Lancet Infectious Diseases

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

71-78

1 reference

Validation of immunoglobulin G enzyme-linked immunosorbent assay for antibodies to pneumococcal surface adhesin A in the diagnosis of pneumococcal pneumonia among adults in Kenya.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Cost-effectiveness of Vaccination Against Pneumococcal Bacteremia Among Elderly People

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Protective Efficacy of Pneumococcal Polysaccharide Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Serotype distribution and prevalence of resistance to benzylpenicillin in three representative populations of Streptococcus pneumoniae isolates from the coast of Kenya.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

An epidemiologic approach to pneumococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Spread of Streptococcus pneumoniae in Families. II. Relation of Transfer of S. pneumoniae to Incidence of Colds and Serum Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Ten-year review of invasive pneumococcal diseases in children and adults from Uruguay: clinical spectrum, serotypes, and antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Bacteriologic diagnosis of acute pneumonia. Comparison of sputum, transtracheal aspirates, and lung aspirates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Spread of Streptococcus pneumoniae in Families. I. Carriage Rates and Distribution of Types

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

A method for assessing the quality of a randomized control trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Prevention of Pneumococcal Infection by Immunization with Capsular Polysaccharides of Streptococcus pneumoniae: Current Status of Polyvalent Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Pneumococcal vaccine: clinical efficacy and effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

The assessment of pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Can meta-analyses be trusted?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Estimating the effects of misclassification.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Pneumonia in old age; active immunization against pneumonia with pneumonococcus polysaccharide; results of a six year study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Inefficacy of pneumococcal vaccine in a high-risk population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Pneumococcal vaccine efficacy in selected populations in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Side effects associated with pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

Safety of revaccination with pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

The prevention of pneumococcal disease by vaccines: promises and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900514-0

7 January 2021

10.1016/S1473-3099(03)00514-0

Identifiers

DOI

1 reference

6 August 2017

1 reference